Literature DB >> 3081597

Inhibition of Pseudomonas aeruginosa from cystic fibrosis by selective media.

K Fonseca, J MacDougall, T L Pitt.   

Abstract

Pseudomonas Isolation Agar (selective agent, Irgasan, 25 mg/1) and Pseudomonas Selective Agar (selective agents, cetrimide 200mg/1 and nalidixic acid 15 mg/1) inhibited some strains of P aeruginosa from cystic fibrosis sputum but did not inhibit isolates from other sources. Of 200 cystic fibrosis isolates, 22 were inhibited by 16 mg/1 Irgasan, 45 by 8 mg/1 nalidixic acid, and 15 by 128 mg/1 cetrimide. We recommend that cystic fibrosis sputum should be cultured on selective and non-selective media to maximise the isolation of P aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081597      PMCID: PMC499682          DOI: 10.1136/jcp.39.2.220

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  Two simple media for the demonstration of pyocyanin and fluorescin.

Authors:  E O KING; M K WARD; D E RANEY
Journal:  J Lab Clin Med       Date:  1954-08

2.  Liquefaction of sputum for bacteriological examination.

Authors:  G A RAWLINS
Journal:  Lancet       Date:  1953-09-12       Impact factor: 79.321

3.  The in vitro antibacterial activity of cefotaxime compared with that of cefuroxime and cefoxitin.

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

4.  Selective media for the quantitation of bacteria in cystic fibrosis sputum.

Authors:  K Wong; M C Roberts; L Owens; M Fife; A L Smith
Journal:  J Med Microbiol       Date:  1984-04       Impact factor: 2.472

5.  Heterogeneity of antibiotic resistance in mucoid isolates of Pseudomonas aeruginosa obtained from cystic fibrosis patients: role of outer membrane proteins.

Authors:  R T Irvin; J W Govan; J A Fyfe; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

6.  The synergism between cetrimide and antibiotics against Pseudomonas aeruginosa.

Authors:  E I el-Nima
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1984-10

7.  The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis.

Authors:  A Penketh; T Pitt; D Roberts; M E Hodson; J C Batten
Journal:  Am Rev Respir Dis       Date:  1983-05
  7 in total
  3 in total

1.  New selective medium for Pseudomonas aeruginosa with phenanthroline and 9-chloro-9-[4-(diethylamino)phenyl]-9,10-dihydro-10- phenylacridine hydrochloride (C-390).

Authors:  M E Campbell; S W Farmer; D P Speert
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

2.  Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe.

Authors:  C Wolz; G Kiosz; J W Ogle; M L Vasil; U Schaad; K Botzenhart; G Döring
Journal:  Epidemiol Infect       Date:  1989-04       Impact factor: 2.451

Review 3.  Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.

Authors:  T L Pitt
Journal:  J R Soc Med       Date:  1986       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.